<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03992560</url>
  </required_header>
  <id_info>
    <org_study_id>1.1</org_study_id>
    <nct_id>NCT03992560</nct_id>
  </id_info>
  <brief_title>A Prospective Randomised Multi-centre Trial Comparing cArdiac MRI Guided CRT Versus Conventional CRT Implantation in Patients With Ischaemic Cardiomyopathy</brief_title>
  <acronym>TACTIC CRT</acronym>
  <official_title>A Prospective Randomised Multi-centre Trial Comparing cArdiac MRI Guided CRT Versus Conventional CRT Implantation in Patients With Ischaemic Cardiomyopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guy's and St Thomas' NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>King's College London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Guy's and St Thomas' NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine whether MRI guided CRT implantation (using Siemen's&#xD;
      software prototype) is superior to standard treatment in terms of CRT response. Data will be&#xD;
      collected at enrolment, implant, pre-discharge, 6 weeks and 6 months. The total duration of&#xD;
      the investigation will be 6 months.&#xD;
&#xD;
      The primary endpoint will be assessed by calculating the difference in the proportion of&#xD;
      responders (&gt;15% reduction in end systolic volume derived from 2-dimensional transthoracic&#xD;
      echocardiogram at 6 months post CRT implant).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 5, 2019</start_date>
  <completion_date type="Anticipated">July 5, 2026</completion_date>
  <primary_completion_date type="Anticipated">July 5, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>&gt;15% reduction in end systolic volume</measure>
    <time_frame>6 months</time_frame>
    <description>&gt;15% reduction in end systolic volume derived from 2-dimensional transthoracic echocardiogram at 6 months post CRT implant</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>5% absolute increase in left ventricular ejection fraction</measure>
    <time_frame>6 months</time_frame>
    <description>5% absolute increase in left ventricular ejection fraction as derived from 2D echocardiogram</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>&gt;10% reduction in end diastolic volume</measure>
    <time_frame>6 months</time_frame>
    <description>&gt;10% reduction in end diastolic volume as derived from 2D echocardiogram</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">218</enrollment>
  <condition>Cardiovascular Diseases</condition>
  <arm_group>
    <arm_group_label>Standard CRT implantation</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>MRI guided CRT implantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Guide CRT Software Prototype</intervention_name>
    <description>The medical device in the trial is a software programme that allows image fusion of previously acquired MRI images with real-time X-Ray fluoroscopic images in the cardiac catheter laboratory. We are able to use the MRI information to assess the best location to place the left ventricular lead for a CRT device and then superimpose this location onto the real-time X-Ray fluoroscopic images during the left ventricular lead implantation</description>
    <arm_group_label>MRI guided CRT implantation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  &gt;18yrs of age&#xD;
&#xD;
          -  Standard indication for CRT-P or CRT-D according to European Society of Cardiology&#xD;
             (ESC)/European Heart Rhythm (EHRA) guidelines.1&#xD;
&#xD;
          -  Stable on optimal medical therapy for at least 3 months&#xD;
&#xD;
          -  Ischaemic aetiology&#xD;
&#xD;
          -  Patients with atrial fibrillation can be included&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any contraindication to pacing /implantable cardioverter-defibrillator (ICD) implant&#xD;
&#xD;
          -  Requirement for endocardial pacing&#xD;
&#xD;
          -  Contraindication to gadolinium contrast enhanced cardiac Magnetic Resonance (MR)&#xD;
             scanning&#xD;
&#xD;
          -  Significant claustrophobia&#xD;
&#xD;
          -  Significant renal impairment with estimated glomerular filtration rate (eGFR) &lt;30&#xD;
             mL/min/1.73m2&#xD;
&#xD;
          -  Existing pacemaker or ICD system or extraction of a CRT system within the last 6&#xD;
             months&#xD;
&#xD;
          -  Participation in other studies with active treatment/ investigational arm&#xD;
&#xD;
          -  Pregnant or planning to become pregnant in the next 7 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Guys and St Thomas NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>SE1 7EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Humra Chadwick</last_name>
      <phone>02071887188</phone>
      <phone_ext>56217</phone_ext>
      <email>humra.chadwick1@gstt.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Aldo Rinaldi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 18, 2019</study_first_submitted>
  <study_first_submitted_qc>June 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 20, 2019</study_first_posted>
  <last_update_submitted>August 6, 2021</last_update_submitted>
  <last_update_submitted_qc>August 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

